• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Hong Kong’s Dept. of Health Taps Biofourmis’ Remote Monitoring Platform to Fight Coronavirus

by Fred Pennic 03/04/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Hong Kong’s Dept. of Health Taps Biofourmis’ Remote Monitoring Platform to Fight Coronavirus

What You Need to Know:

– Boston-based Biofourmis’ AI-powered digital therapeutics technology has inked a deal with The University of Hong Kong and Hong Kong’s Department of Health to leverage its wearable, AI-powered remote monitoring platform to provide new insights to fight COVID-19 in a national disease monitoring program.

– Biofourmis’ technology will remotely monitor coronavirus infected and suspected patients and apply personally predictive analytics to help patients and increase COVID-19 knowledge.

– This first-of-its-kind program—which has international implications and applications—points to the value of the emerging category of digital therapeutics in monitoring patients with diagnosed or suspected COVID-19, while also helping clinicians better understand the disease so that they can better treat it.


As the novel coronavirus (COVID-19) continues to spread, Boston-based Biofourmis is being leveraged in a remote monitoring and disease surveillance program in Hong Kong involving patients with diagnosed or suspected novel coronavirus disease (COVID-19). The national disease monitoring program—administered by The University of Hong Kong’s Department of Health—also includes Hong Kong-based Harmony Medical Inc., which is Biofourmis’ joint venture partner for the China region.

Remote Patient Monitoring to Identify COVID-19-Related Physiological Biomarkers

Diagnosed and potentially COVID-19-infected patients are being monitored with Biofourmis’ Biovitals® Sentinel platform, a turn-key solution that the company built in less than two weeks specifically for this initiative by customizing its FDA-cleared artificial intelligence (AI)-powered Biovitals® Analytics platform. Biovitals Sentinel’s 24/7 remote monitoring technology and analytics are providing clinicians involved in the COVID-19 program with clinical decision support for early identification of any physiological changes that could indicate deterioration, to enable earlier interventions for better outcomes.

“The goal of this program is to leverage Biovitals® Sentinel to remotely monitor patients and identify COVID-19-related physiological biomarkers that indicate deterioration in patients,” said Prof. David Chung Wah Siu, MD, Department of Medicine, The University of Hong Kong. “We hope our combined efforts also will rapidly lead to a better epidemiological understanding of COVID-19 so we can improve the outcomes of our citizens—as well as the global community—as more people become infected.”

How the Disease Monitoring Program Works

Hong Kong’s Dept. of Health Taps Biofourmis’ Remote Monitoring Platform to Fight Coronavirus

Patients with COVID-19 deterioration commonly exhibit symptoms such as fever, cough and shortness of breath, all of which can be closely monitored through related physiological parameters via Biofourmis’ cutting-edge, clinical-grade biosensor Everion®, which is being worn on the arm by patients quarantined in their homes or clinical settings. Clinicians and researchers are still learning how this strain of the coronavirus affects the body, and the research will help elucidate that.

To measure body temperature and numerous other biomarkers, patients are wearing Everion, which has several medical-grade sensors, including optical, temperature, electrodermal, accelerometer and barometer. Everion® can be comfortably worn for 24 hours a day for several days and has much higher-than-average patient satisfaction and adherence rates. AI-powered Biovitals® Analytics will derive more than 20 physiological signals from the sensor data, including temperature, heart rate, blood pulse wave, heart rate variability, respiration rate, inter-beat-interval and others. These signals are then fed through advanced AI and machine-learning techniques to flag key physiological changes that could indicate disease progression. 

The Biovitals®Sentinel solution also includes a smartphone app to collect qualitative data reported by patients as they respond to AI-generated “smart nuggets.”  Treating physicians, through the Biovitals Sentinel clinician-facing web dashboard, will observe and be alerted to any significant physiological changes and adverse events, so they can intervene when necessary. 

The Impact of Accelerated COVID-19 Deterioration Identification

“The sooner these biomarkers associated with COVID-19 deterioration are identified, the sooner healthcare providers can intervene and prevent a serious medical issue,” said Kuldeep Singh Rajput, CEO of Biofourmis. “We currently know the common symptoms, but we are still learning how this strain of the coronavirus affects the body. This program will be a key step in achieving this important goal. When a pandemic such as COVID-19 spreads and so much is unknown, every second counts.” 

Global Implications for Disease Monitoring Program

Dr. Raymond Tong, CEO of Harmony Medical Inc., Biofourmis’ joint venture partner for the China region, added: “With this special partnership with The University of Hong Kong and its leading experts in the field, we are tackling the coronavirus in a rapid and an unprecedented fashion, which could potentially save lives.”

Future Expansion Plans to Other Government Agencies Worldwide to Fight COVID-19

Biofourmis is in conversations with government agencies in other regions about applying its technology to help even more patients and fight against the global spread of COVID-19 so that it can be treated more effectively. “The Biovitals® Sentinel solution is scalable and ready to be deployed in any country or region that wants to engage in similar disease monitoring or for patient care delivery,” Rajput said. “We look forward to helping any other academic medical and/or government agencies that would be interested in a similar partnership.”


  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, Artificial Intelligence, Biofourmis, Biomarkers, Clinical Decision Support, decision support, Digital Therapeutics, FDA, Heart, MD, Patient Care, Patient Monitoring, Patient Satisfaction, physicians, Predictive Analytics, remote patient monitoring, sensors

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

5 Ways New Trump Administration Tariffs Are Impacting U.S. Healthcare Now

5 Ways Trump Administration Tariffs Are Impacting U.S. Healthcare Now

iCAD, GE HealthCare Integrate to Advance Breast Cancer Detection with AI

RadNet to Acquire iCAD for $103M in All-Stock Transaction

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |